Low-molecular-weight heparin (dalteparin) demonstrated a weaker effect on rat bone metabolism compared with heparin

被引:20
|
作者
Nishiyama, M
Itoh, F
Ujiie, A
机构
[1] Central Research Laboratories, Kissei Pharmaceutical Co., Ltd., Hotaka, Nagano 399-83, 4365-1, Kashiwabara
来源
JAPANESE JOURNAL OF PHARMACOLOGY | 1997年 / 74卷 / 01期
关键词
heparin; dalteparin sodium; bone metabolism; osteopenia;
D O I
10.1254/jjp.74.59
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We studied the pharmacological effects of dalteparin (low-molecular-weight heparin) and heparin on bone metabolism in rats. After their 28 days of consecutive intravenous injections, significant loss of bone weight and mineral contents was observed in the heparin-treated rats, whereas dalteparin slightly reduced bone mass. By the end of the experiment, the femora of 7 out of 8 rats fractured in the heparin (10,000 U/kg/day)-treated group, but none had broken in the control and dalteparin-treated groups. Serum osteocalcin levels were significantly decreased in the former group. The growth plate width of the tibia was increased in a dose-dependent manner, especially in the heparin-treated group. Histomorphometric assessment of tibia showed that the osteoid surface and mineral apposition rates were significantly reduced in the heparin-treated group, whereas the eroded surface was significantly increased in the heparin-treated group. The above results suggest that heparin not only augments bone resorption but also suppressed bone formation and that dalteparin has a weaker suppressive effect on bone formation compared with heparin.
引用
收藏
页码:59 / 68
页数:10
相关论文
共 50 条
  • [21] ANTICOAGULANT EFFECT OF A LOW-MOLECULAR-WEIGHT HEPARIN
    HARENBERG, J
    ZIMMERMAN, R
    DEVRIES, JX
    WEBER, E
    MUNCHENER MEDIZINISCHE WOCHENSCHRIFT, 1986, 128 (29-30): : 541 - 542
  • [22] Anticoagulation with low-molecular-weight heparin (dalteparin) in plasmapheresis therapy: initial experience
    Schinzel, H
    Berghoff, K
    Beuermann, I
    Sauer, O
    von Mach, MA
    Weilemann, LS
    TRANSFUSION, 2006, 46 (04) : 624 - 629
  • [23] The effect of low-molecular-weight heparin on microvenous thrombosis in a rat model
    Emerick, Kevin S.
    Deschler, Daniel G.
    ARCHIVES OF FACIAL PLASTIC SURGERY, 2007, 9 (01) : 19 - 21
  • [24] Portable Compression Device and Low-Molecular-Weight Heparin Compared With Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Joint Arthroplasty
    Edwards, John Z.
    Pulido, Pamela A.
    Ezzet, Kace A.
    Copp, Steven N.
    Walker, Richard H.
    Colwell, Clifford W., Jr.
    JOURNAL OF ARTHROPLASTY, 2008, 23 (08): : 1122 - 1127
  • [25] Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury
    Malm, K
    Dahlbäck, B
    Arnljots, B
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2003, 111 (05) : 1659 - 1666
  • [26] PHARMACOKINETICS OF UNFRACTIONATED HEPARIN AND OF LOW-MOLECULAR-WEIGHT HEPARIN
    BONEU, B
    THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 872 - 872
  • [27] Unfractionated heparin or low-molecular-weight heparin in the elderly
    Dorobantu, Maria
    Bogdan, Stefan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 222 : 1084 - 1090
  • [28] Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo
    Norrby, Klas
    Nordenhem, Arvid
    APMIS, 2010, 118 (12) : 949 - 957
  • [29] THE EFFECT OF LOW-MOLECULAR-WEIGHT HEPARIN ON THE WHOLE-BLOOD ACTIVATED CLOTTING TIME AS COMPARED WITH STANDARD HEPARIN
    MESSMORE, HL
    FARID, S
    FABBRINI, N
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 1111 - 1111
  • [30] Pharmacokinetics of the low molecular weight heparin dalteparin in cats
    Mischke, Reinhard
    Schmitt, Judith
    Wolken, Sonja
    Boehm, Claudia
    Wolf, Petra
    Kietzmann, Manfred
    VETERINARY JOURNAL, 2012, 192 (03): : 299 - 303